导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.35% | 1855/4773 |
| 近一周 | -2.72% | 4198/5465 |
| 近一月 | 0.52% | 537/5421 |
| 近一季 | -2.23% | 1331/5231 |
| 近半年 | -11.77% | 3759/4920 |
| 近一年 | 9.97% | 1145/4394 |
| 近两年 | 43.08% | 1765/2954 |
| 近三年 | 28.43% | 1147/2253 |
| 成立以来 | 94.21% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
8.79% 102/4961 |
-6.25% 3677/5312 |
- - |
- - |
| 2025 | 15.57% 2532/4813 |
-1.81% 2784/3635 |
1.33% 2378/4076 |
9.73% 3337/4524 |
5.87% 394/4813 |
| 2024 | 16.65% 784/3463 |
7.04% 265/2808 |
1.29% 484/3014 |
9.87% 2660/3129 |
-2.08% 1947/3463 |
| 2023 | -1.03% 489/2656 |
12.29% 304/2280 |
0.94% 263/2385 |
-6.39% 1474/2515 |
-6.72% 1889/2655 |
| 2022 | -12.45% 286/2207 |
-7.87% 258/1919 |
5.03% 947/2016 |
-11.77% 578/2113 |
2.55% 900/2208 |
| 2021 | 14.94% 316/1822 |
5.13% 121/1255 |
4.75% 850/1330 |
5.61% 265/1466 |
-1.16% 1321/1822 |
| 2020 | - - |
- - |
0.43% 1003/1067 |
10.88% 500/1164 |
11.93% 508/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 易方达中证国企带路发起式联接C VS. 长安沪深300非周期A(740101) |